• We are sorry, but NCBI web applications do not support your browser and may not function properly. More information
Logo of jcmPermissionsJournals.ASM.orgJournalJCM ArticleJournal InfoAuthorsReviewers
J Clin Microbiol. Jan 1986; 23(1): 73–76.
PMCID: PMC268575

Resistance of adults to challenge with influenza A wild-type virus after receiving live or inactivated virus vaccine.

Abstract

The efficacy of live attenuated cold-adapted (ca) reassortant influenza A H3N2 and H1N1 virus vaccines against experimental challenge with homologous wild-type virus 7 months after vaccination was compared with that of licensed inactivated virus vaccine in 106 seronegative (hemagglutination-inhibiting antibody titer less than or equal to 1:8) college students. The live attenuated virus vaccines induced as much resistance against illness as did the inactivated vaccine. Vaccine efficacy, measured by reduction in febrile or systemic illness in vaccines, compared with that in controls was 100% for ca H3N2 vaccine, 84% for inactivated H3N2 vaccine, 79% for ca H1N1 vaccine, and 67% for inactivated H1N1 vaccine. Less protection was conferred against upper respiratory tract illness; there was 50 and 77% protection in ca and inactivated H3N2 vaccines, respectively, but there was no protection in ca or inactivated H1N1 vaccinees. The duration, but not the magnitude, of H1N1 wild-type virus shedding in both ca and inactivated vaccinees was significantly reduced compared with controls. In contrast, a significant reduction in the duration and magnitude of H3N2 virus shedding was observed in ca vaccinees but not in inactivated vaccines. After wild-type virus challenge, live ca virus vaccinees demonstrated resistance at least as great 7 months postvaccination as did inactivated virus vaccinees. These observations indicate that live virus vaccines may be a satisfactory alternative to inactivated vaccines for healthy persons.

Full text

Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (852K), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Belshe RB, Van Voris LP. Cold-recombinant influenza A/California/10/78 (H1N1) virus vaccine (CR-37) in seronegative children: infectivity and efficacy against investigational challenge. J Infect Dis. 1984 May;149(5):735–740. [PubMed]
  • Betts RF, Douglas RG, Jr, Murphy BR. Resistance to challenge with influenza A/Hong Kong/123/77 (H1N1) wild-type virus induced by live attenuated A/Hong Kong/123/77 (H1N1) cold-adapted reassortant virus. J Infect Dis. 1985 Apr;151(4):744–745. [PubMed]
  • Clements ML, Betts RF, Maassab HF, Murphy BR. Dose response of influenza A/Washington/897/80 (H3N2) cold-adapted reassortant virus in adult volunteers. J Infect Dis. 1984 May;149(5):814–815. [PubMed]
  • Clements ML, Betts RF, Murphy BR. Advantage of live attenuated cold-adapted influenza A virus over inactivated vaccine for A/Washington/80 (H3N2) wild-type virus infection. Lancet. 1984 Mar 31;1(8379):705–708. [PubMed]
  • Clements ML, Murphy BR. Development and persistence of local and systemic antibody responses in adults given live attenuated or inactivated influenza A virus vaccine. J Clin Microbiol. 1986 Jan;23(1):66–72. [PMC free article] [PubMed]
  • Foy HM, Cooney MK, McMahan R, Bor E, Grayston JT. Single-dose monovalent A 2 -Hong Kong influenza vaccine. Efficacy 14 months after immunization. JAMA. 1971 Aug 23;217(8):1067–1071. [PubMed]
  • Hoskins TW, Davies JR, Smith AJ, Miller CL, Allchin A. Assessment of inactivated influenza-A vaccine after three outbreaks of influenza A at Christ's Hospital. Lancet. 1979 Jan 6;1(8106):33–35. [PubMed]
  • Johnson PR, Jr, Feldman S, Thompson JM, Mahoney JD, Wright PF. Comparison of long-term systemic and secretory antibody responses in children given live, attenuated, or inactivated influenza A vaccine. J Med Virol. 1985 Dec;17(4):325–335. [PubMed]
  • Murphy BR, Clements ML, Madore HP, Steinberg J, O'Donnell S, Betts R, Demico D, Reichman RC, Dolin R, Maassab HF. Dose response of cold-adapted, reassortant influenza A/California/10/78 virus (H1N1) in adult volunteers. J Infect Dis. 1984 May;149(5):816–816. [PubMed]
  • Murphy BR, Nelson DL, Wright PF, Tierney EL, Phelan MA, Chanock RM. Secretory and systemic immunological response in children infected with live attenuated influenza A virus vaccines. Infect Immun. 1982 Jun;36(3):1102–1108. [PMC free article] [PubMed]
  • Murphy BR, Phelan MA, Nelson DL, Yarchoan R, Tierney EL, Alling DW, Chanock RM. Hemagglutinin-specific enzyme-linked immunosorbent assay for antibodies to influenza A and B viruses. J Clin Microbiol. 1981 Mar;13(3):554–560. [PMC free article] [PubMed]
  • Murphy BR, Clements ML, Tierney EL, Black RE, Stienberg J, Chanock RM. Dose response of influenza A/Washington/897/80 (H3N2) avian-human reassortant virus in adult volunteers. J Infect Dis. 1985 Jul;152(1):225–229. [PubMed]
  • Ruben FL, Akers LW, Stanley ED, Jackson GG. Protection with split and whole virus vaccines against influenza. Arch Intern Med. 1973 Oct;132(4):568–571. [PubMed]
  • Wright PF, Okabe N, McKee KT, Jr, Maassab HF, Karzon DT. Cold-adapted recombinant influenza A virus vaccines in seronegative young children. J Infect Dis. 1982 Jul;146(1):71–79. [PubMed]

Articles from Journal of Clinical Microbiology are provided here courtesy of American Society for Microbiology (ASM)

Formats:

Related citations in PubMed

See reviews...See all...

Cited by other articles in PMC

See all...

Links

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...